Skip to content
The Policy VaultThe Policy Vault

XifaxanUnited Healthcare

Hepatic Encephalopathy

Preferred products

  • lactulose

Initial criteria

  • Diagnosis of hepatic encephalopathy
  • Used as add-on therapy to lactulose AND patient is unable to achieve an optimal clinical response with lactulose monotherapy OR history of contraindication or intolerance to lactulose

Reauthorization criteria

  • Documentation of positive clinical response to Xifaxan therapy

Approval duration

12 months